AU2022376165A1 - Compositions comprising an erk inhibitor - Google Patents
Compositions comprising an erk inhibitor Download PDFInfo
- Publication number
- AU2022376165A1 AU2022376165A1 AU2022376165A AU2022376165A AU2022376165A1 AU 2022376165 A1 AU2022376165 A1 AU 2022376165A1 AU 2022376165 A AU2022376165 A AU 2022376165A AU 2022376165 A AU2022376165 A AU 2022376165A AU 2022376165 A1 AU2022376165 A1 AU 2022376165A1
- Authority
- AU
- Australia
- Prior art keywords
- weight
- solid dispersion
- compound
- solvate
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163271977P | 2021-10-26 | 2021-10-26 | |
| US63/271,977 | 2021-10-26 | ||
| PCT/US2022/047769 WO2023076305A1 (en) | 2021-10-26 | 2022-10-25 | Compositions comprising an erk inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022376165A1 true AU2022376165A1 (en) | 2024-05-16 |
Family
ID=84367494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022376165A Pending AU2022376165A1 (en) | 2021-10-26 | 2022-10-25 | Compositions comprising an erk inhibitor |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240415835A1 (https=) |
| EP (1) | EP4422604A1 (https=) |
| JP (1) | JP2024539891A (https=) |
| KR (1) | KR20240089586A (https=) |
| CN (1) | CN118119381A (https=) |
| AU (1) | AU2022376165A1 (https=) |
| CA (1) | CA3235680A1 (https=) |
| WO (1) | WO2023076305A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE068392T2 (hu) * | 2015-10-21 | 2024-12-28 | Otsuka Pharma Co Ltd | Benzolaktám vegyületek mint fehérje kináz gátlók |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE068392T2 (hu) | 2015-10-21 | 2024-12-28 | Otsuka Pharma Co Ltd | Benzolaktám vegyületek mint fehérje kináz gátlók |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
-
2022
- 2022-10-25 US US18/702,752 patent/US20240415835A1/en active Pending
- 2022-10-25 AU AU2022376165A patent/AU2022376165A1/en active Pending
- 2022-10-25 KR KR1020247015609A patent/KR20240089586A/ko active Pending
- 2022-10-25 EP EP22814554.6A patent/EP4422604A1/en active Pending
- 2022-10-25 CA CA3235680A patent/CA3235680A1/en active Pending
- 2022-10-25 CN CN202280070421.4A patent/CN118119381A/zh active Pending
- 2022-10-25 WO PCT/US2022/047769 patent/WO2023076305A1/en not_active Ceased
- 2022-10-25 JP JP2024523533A patent/JP2024539891A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3235680A1 (en) | 2023-05-04 |
| US20240415835A1 (en) | 2024-12-19 |
| JP2024539891A (ja) | 2024-10-31 |
| EP4422604A1 (en) | 2024-09-04 |
| KR20240089586A (ko) | 2024-06-20 |
| CN118119381A (zh) | 2024-05-31 |
| WO2023076305A1 (en) | 2023-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240415835A1 (en) | Compositions comprising an erk inhibitor | |
| US10034854B2 (en) | Pharmaceutical composition with improved bioavailability | |
| WO2009129301A2 (en) | Oral pharmaceutical compositions in a molecular solid dispersion | |
| US12502384B2 (en) | Pharmaceutical composition containing nitroxoline prodrug, and preparation method and application therefor | |
| CN1227001C (zh) | 依托度酸的缓释制剂 | |
| WO2019142207A1 (en) | Pharmaceutical compositions comprising ibrutinib | |
| TWI837095B (zh) | 一種醫藥組成物及其製備方法 | |
| CN114832112A (zh) | 含有alk激酶抑制剂的药物制剂组合物及其制备方法 | |
| CN115397416B (zh) | 包含仑伐替尼的分子水平的药物组合物及其制备方法和应用 | |
| TW202419085A (zh) | 含erk抑制劑之組合物 | |
| CN115025048A (zh) | 一种阿瑞匹坦的三元固体分散体 | |
| WO2017116031A1 (ko) | 유당불내성 환자에게 투여가 가능하며, 복용편의성이 향상된 게피티니브를 함유하는 약제학적 조성물 | |
| HK40111112A (zh) | 包含erk抑制剂的组合物 | |
| TWI901422B (zh) | 一種嘧啶類衍生物的藥物組合物 | |
| US20190054073A1 (en) | Pharmaceutical composition comprising pyrrolo-fused six-membered heterocyclic compound | |
| TR2022009483A2 (tr) | Palbosiklib içeren bir farmasötik bileşim. | |
| CN120983371A (zh) | 一种btk抑制剂固体片剂及其制备方法 | |
| TR2022009480A1 (tr) | Palbosiklib içeren bir farmasötik bileşim. | |
| CN120939011A (zh) | 喹唑啉类化合物的药物制剂及其制备方法和用途 | |
| TR2022009484A2 (tr) | Palbosiklib içeren oral uygulama için bir tablet. | |
| WO2026021558A1 (zh) | 一种药物制剂组合物及其制备方法 | |
| WO2025122074A1 (en) | Low dose riociguat compositions | |
| EP4626434A1 (en) | Solid dispersion comprising amorphous 2-[3-[4-(lh-indazol-5- ylamino)quinazolin-2-yl]phenoxy]-n-propan-2-yl-acetamide | |
| WO2025083622A1 (en) | Pharmaceutical composition with improved drug release and preparation method thereof | |
| TW202245787A (zh) | 喹唑啉化合物及藥物組合物的應用 |